PEComa Market is Projected to Reach USD 135 Million by 2036, Driven by Rising Incidence and Expanding Targeted and Combination Therapy Opportunities

PEComa Market is Projected to Reach USD 135 Million by 2036, Driven by Rising Incidence and Expanding Targeted and Combination Therapy Opportunities | DelveInsight https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr https://www.abnewswire.com/email_contact_us.php?pr=pecoma-market-is-projected-to-reach-usd-135-million-by-2036-driven-by-rising-incidence-and-expanding-targeted-and-combination-therapy-opportunities-delveinsight https://www.delveinsight.com/ DelveInsight's latest report, "PEComa Market Insights, Epidemiology and Market Forecast - 2036," provides a comprehensive analysis of the Perivascular Epithelioid Cell Neoplasm (PEComa) market across the United States, EU4, the United Kingdom, and Japan. According to DelveInsight's estimates, the PEComa market size in the 7MM was approximately USD 45 million in 2025 and is projected to reach approximately USD 135 million by 2036, growing at a CAGR of 8.1% during 2026-2036.(Albany, New York)- 7th Sep 2026 - DelveInsight's latest report, "PEComa Market Insights, Epidemiology and Market Forecast - 2036," provides a comprehensive analysis of the Perivascular Epithelioid Cell Neoplasm (PEComa) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. According to DelveInsight's estimates, the PEComa market size in the 7MM was approximately USD 45 million in 2025 and is projected to reach approximately USD 135 million by 2036, growing at a CAGR of 8.1% during 2026-2036.The PEComa treatment landscape is evolving from reliance on surgery and limited systemic therapies toward more targeted, molecularly driven treatment approaches. The FDA approval of FYARRO (sirolimus protein-bound) has established mTOR inhibition as an important therapeutic strategy for advanced PEComa, while emerging therapies such as immune checkpoint inhibitors are expected to further expand treatment opportunities.Key Takeaways from the PEComa MarketThe 7MM PEComa market size was approximately USD 45 million in 2025 and is projected to reach USD 135 million by 2036, registering a CAGR of 8.1% during 2026-2036.The PEComa market size in the leading markets was approximately USD 43 million in 2025.The total prevalent cases of PEComa across the 7MM were approximately 408 in 2025.Malignant PEComas are estimated to be diagnosed in approximately 0.12-0.24 per 1 million people.FYARRO (sirolimus protein-bound) is currently the only FDA-approved therapy specifically indicated for PEComa, having received FDA approval in November 2021.In the United States in 2025, benign tumors accounted for approximately 67% of PEComa cases by stage, while local aggressive behavior/malignant PEComa accounted for approximately 33%.The United States is expected to remain the largest PEComa market, reaching approximately USD 114 million by 2036.FYARRO is estimated to generate the highest revenue among PEComa therapies in the United States in 2036.Key companies involved in the PEComa treatment landscape include Aadi Bioscience, Merck Sharp & Dohme, and others.Keen to know more about the PEComa Market Report?Key Factors Driving the PEComa MarketRising Incidence of PEComaThe increasing incidence and recognition of PEComa are expected to contribute to market expansion during the forecast period. Although PEComa is a rare tumor, it can occur across a broad age range and may develop sporadically or in association with Tuberous Sclerosis Complex (TSC). Increasing disease awareness and improvements in diagnosis are expected to support identification of additional cases.Expanding Targeted Therapy OpportunitiesThe approval of FYARRO has significantly advanced the treatment landscape for advanced and metastatic PEComa. As an mTOR inhibitor, FYARRO targets a pathway frequently dysregulated in PEComa and provides a targeted therapeutic option for patients with locally advanced unresectable or metastatic disease. Continued research into molecular drivers such as TSC1/TSC2 alterations is expected to support further development of targeted therapies.Growing Interest in Combination TherapiesThe PEComa treatment landscape is increasingly exploring combination approaches involving targeted therapies, immune checkpoint inhibitors, and anti-angiogenic agents. The development of these strategies could provide additional options for patients with advanced or refractory disease and potentially address limitations associated with currently available therapies.Increasing Focus on Precision MedicineMolecular characterization of PEComa is becoming increasingly important in treatment decision-making. The association of PEComa with mTOR pathway alterations and TSC1/TSC2 abnormalities is supporting the development of more personalized treatment strategies. This shift toward molecularly guided treatment is expected to create additional opportunities within the PEComa market.Competitive LandscapeThe PEComa market currently has a limited number of approved systemic treatment options, with FYARRO (sirolimus protein-bound/ABI-009) representing the only FDA-approved systemic therapy specifically for PEComa.FYARRO, developed by Kaken Pharmaceutical, is an intravenous nanoparticle albumin-bound formulation of sirolimus that inhibits the mTOR pathway. It was approved in 2021 for adults with locally advanced, unresectable, or metastatic PEComa.The emerging PEComa landscape includes Pembrolizumab (KEYTRUDA) from Merck Sharp & Dohme. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1 and is being explored in advanced or refractory PEComa, although it is not specifically approved for this indication.Other systemic treatment approaches include sirolimus, everolimus, and temsirolimus, which are listed in NCCN guidelines as systemic therapy agents with activity in PEComa. Cytotoxic chemotherapy and VEGF/VEGFR-directed approaches may also be considered in selected cases.Recent Developments in the PEComa MarketMarch 2025: Aadi Bioscience was reorganized into two entities following the divestiture of Aadi Sub to KAKEN. KAKEN assumed ownership of Aadi Sub, including the Aadi name, trademark, and FYARRO business, while the remaining parent company was renamed Whitehawk Therapeutics and focused on its ADC portfolio.December 2024: Aadi Bioscience entered an agreement to sell its commercial drug FYARRO to KAKEN Pharmaceutical for USD 100 million, alongside a USD 100 million PIPE equity financing and an exclusive license for a three-asset preclinical ADC portfolio. The transaction was approved by Aadi's stockholders in March 2025.July 2022: FYARRO received a permanent J-code (J9331) from CMS, effective July 1, 2022, supporting reimbursement and access across US care settings.What is Perivascular Epithelioid Cell Neoplasm (PEComa)?Perivascular Epithelioid Cell Neoplasm (PEComa) is a rare mesenchymal tumor characterized by perivascular epithelioid cells with both melanocytic and smooth muscle features. PEComas can occur in multiple organs, particularly the uterus, kidney, liver, and retroperitoneum, and may be associated with Tuberous Sclerosis Complex.Patients may be asymptomatic, while clinical manifestations depend largely on the tumor's location and size. Diagnosis is primarily based on histopathological examination and immunohistochemistry, with tumor cells typically expressing melanocytic markers such as HMB-45 and Melan-A along with smooth muscle markers. Imaging techniques such as CT and MRI assist in determining tumor location and extent, while biopsy is required for definitive diagnosis.Current Treatment LandscapeTreatment for PEComa depends on disease stage, tumor resectability, molecular characteristics, and clinical presentation. Surgical resection with negative margins remains the primary curative approach for localized disease.For advanced, unresectable, or metastatic disease, FYARRO represents the only FDA-approved systemic therapy specifically indicated for PEComa. Other mTOR inhibitors, including sirolimus, everolimus, and temsirolimus, may be used as systemic treatment options. Chemotherapy and radiotherapy generally have limited roles, while targeted therapies and immune checkpoint inhibitors are being investigated in selected patients.PEComa Epidemiology SegmentationThe PEComa epidemiology analysis covers:Total Incident Cases of Perivascular Epithelioid Cell Neoplasm (PEComa)Gender-specific Incident CasesStage-specific Incident CasesPEComa Cases by Clinical PresentationAge-specific Incident CasesAccording to DelveInsight, the total prevalent cases of PEComa in the 7MM were approximately 408 in 2025. Among the EU4 and the UK, Germany accounted for the highest incidence, followed by France and the UK. In the United States, benign tumors represented approximately 67% of cases by stage in 2025, while local aggressive behavior/malignant PEComa represented approximately 33%.Scope of the PEComa Market ReportStudy Period: 2022-2036Historical Year: 2022-2025Forecast Period: 2026-2036Base Year: 2026Geographies Covered: United States, Germany, France, Italy, Spain, United Kingdom, and JapanMarket CAGR: 8.1% (2026-2036)Epidemiology Segmentation: Total incident cases, gender-specific incident cases, stage-specific incident cases, cases by clinical presentation, and age-specific incident casesMarket Segmentation: Region/Geographies and Drugs/TherapiesKey Companies Covered: Aadi Bioscience, Merck Sharp & Dohme, and othersKey Therapies Covered: Sirolimus protein-bound/ABI-009 (FYARRO), Pembrolizumab (KEYTRUDA), and othersMarket Analysis: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, and patient burden assessmentReport Assessment: Current treatment practices, unmet needs, clinical development analysis, emerging drug product profiles, market attractiveness, competitive landscape, pricing and analogue assessment, drug adoption/uptake, and peak patient share analysis.To know more about the PEComa market, clinical development, emerging therapies, and therapeutic assessment: View the PEComa Market Report [Table of ContentsKey InsightsReport IntroductionExecutive SummaryKey EventsEpidemiology and Market Forecast MethodologyPEComa Market Overview at a GlanceDisease Background and Overview of Perivascular Epithelioid Cell Neoplasm (PEComa)Treatment Guidelines of PEComaEpidemiology and Patient Population of PEComaDrug Chapters and Competitive AnalysisMarketed TherapiesEmerging TherapiesPEComa Market OutlookDrug Uptake and Market ForecastMarket Access and ReimbursementPricing and Cost AnalysisIndustry Experts and Physician ViewsSWOT and Conjoint AnalysisUnmet NeedsMarket Drivers and BarriersCompetitive LandscapeAppendixMethodologyAbout DelveInsightAbout DelveInsightDelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail:Send Email [Phone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NevadaCountry: United StatesWebsite:Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com